AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present new safety data from AVROBIO’s clinical trials in Fabry disease and Gaucher disease type 1 at the virtual 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Oct. 19-22, 2021.
Clinical and preclinical data from across the company’s pipeline of lysosomal disorder gene therapy programs will be included in two oral presentations and five poster presentations. Additionally, AVROBIO will sponsor a symposium on Wednesday, Oct. 20, 2021, on “Advancing the patient experience during ex vivo lentiviral gene therapy for lysosomal disorders.”
The presentations are listed below, and the full program is available online at the ESGCT website.